Concordance of patient and clinical ratings of symptom severity and change of psychotic illness-Reference-Cited by-同舟云学术

Concordance of patient and clinical ratings of symptom severity and change of psychotic illness

Published:2008-03 Issue:1-3 Volume:100 Page:359-360
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Rabinowitz Jonathan,Levine Stephen Z.,Medori Rossella,Oosthuizen Petrus,Koen Liezl,Emsley Robin

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference7 articles.

1. Emsley, R., Medori, R., Koen, L., et al., 2007. Long-acting injectable risperidone in the treatment of subjects with recent onset psychosis: a preliminary study. Under journal review.

2. ECDEU Assessment Manual for Psychopharmacology (Revised edn);Guy,1976

3. The positive and negative syndrome scale (PANSS) for schizophrenia;Kay;Schizophr. Bull.,1987

4. Linking the PANSS, BPRS, and CGI: clinical implications;Leucht;Neuropsychopharmacology,2006

5. Levine, S.Z., Rabinowitz, J., Engel, R., et al., in press. Extrapolation between measures of symptom severity and change: The case of the PANSS and CGI. Schizophr Res. (Available online 18 October 2007).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Awareness of illness moderates self-assessment of psychotic symptoms;Australian & New Zealand Journal of Psychiatry;2021-11-17

2. Psychometric properties and normative data of the Spanish version of short form persecution and deservedness scale;Psychosis;2020-11-10

3. Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms;Schizophrenia Bulletin;2020-11-09

4. Differences between self-reported and clinician-rated evaluations of 1-year changes in auditory verbal hallucinations among schizophrenia patients;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2019-12

5. Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance;European Neuropsychopharmacology;2015-10